The USPTO published patent application US20260091109A1 disclosing a method for treating Alzheimer's disease by sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to a human patient. Preferred embodiments involve administering the antibody in increasing amounts over time to reduce susceptibility to amyloid related imaging abnormalities (ARIA). The application was filed June 16, 2025, and names James L. Ferrero, Leslie Lugene Williams, and Jeffrey Joseph Sevigny as inventors.

This is a patent application publication only. It provides public notice of a pending application but creates no compliance obligations for third parties. No action is required by pharmaceutical or biotechnology companies. Parties interested in the patent landscape for Alzheimer's treatments may review the application through USPTO records.